Erasca is a clinical-stage, precision oncology company with a bold mission—to erase cancer. We are focused on the discovery, development and commercialization of novel therapies and combination regimens designed to comprehensively shut down cancer’s most commonly mutated signaling cascade, the RAS/MAPK pathway, linked to approximately 5.5 million new cases of cancer per year worldwide, over 90% of which have limited or no treatment options. Our robust, rapidly advancing pipeline of promising therapeutic candidates has the potential to improve the treatment of a range of RAS/MAPK pathway-related cancers—and in turn, transform millions of lives.

To date, we have been supported by a leading syndicate of investors which include our founding investors, City Hill Ventures and Cormorant Asset Management, and ARCH Venture Partners, Andreessen Horowitz, Colt Ventures, edbi, Invus, LifeSci Venture Partners, OrbiMed Healthcare Fund Management, PFM Health Sciences, and Terra Magnum.

Latest Presentation

More information is coming soon.